2. Immunology/Inflammation
  3. CD19
  4. Blinatumomab

Blinatumomab  (Synonyms: bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO)

Cat. No.: HY-P9963 Purity: 97.33%
COA
SDS
Technical Support

Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia.

For research use only. We do not sell to patients.

CAS No. : 853426-35-4

Size Price Stock Quantity
100 μg In-stock
500 μg In-stock
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Blinatumomab Featured Recommendations:

Blinatumomab Related Antibodies

Top Publications Citing Use of Products
Others

    Blinatumomab purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Jun 18;5(6):101590.  [Abstract]

    Histogram of the percentage of conjugated cells when 2 × 105 Dye 670-stained NY-ESO-1157-165-primed HLA-A∗0201-Raji cells were cocultured 1 h with mixed 2 × 104 CFSE-stained 1G4-PD-1-Jurkat cells and 2 × 104 Dye 450-stained PD-1-Jurkat cells. The concentration of αPD-1-(iRGD)2 was 10 μg/mL, while Blinatumomab (1 μg/mL; 1 h) .

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia[1][2][3][4].

    Isotype

    (scFv-kappa-heavy)-(scFv-heavy-kappa)
    Species Reactivity

    Human
    IC50 & Target

    CD19 & CD3E
    In Vivo

    Blinatumomab (0.01-1 μg, i.v. once daily for 5 days) extended the survival of mice in a dose-dependent manner in a leukemic nonobese diabetic SCID mouse model[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: leukemic nonobese diabetic SCID mouse model (20 days old)[2]
    Dosage: 0.01-1 μg
    Administration: Intravenous injection (i.v.), once daily for 5 days
    Result: Caused none of the animals developed detectable tumors and survived inoculation of NALM-6 cells at cumulative doses of 5 or 0.5 μg for the entire observation period of 76 days. Cumulative doses of 0.05 and 0.005 μg were not effective in preventing tumor growth.
    Clinical Trial
    Gene ID

    12479  [NCBI] & 916  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    54.09 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Blinatumomab]
    Shipping

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • (scFv-kappa-heavy)-(scFv-heavy-kappa)
    Biological Activity
    • Loaded Blinatumomab on CM5 Chip, can bind CD19 Protein, Human (CHO, Fc, HY-P7333) with an affinity constant of 11.02E-9 M as determined in SPR assay.
    • Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Blinatumomab (HY-P9963). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
    Purity & Documentation

    Purity: 98.78%

    SDS (252 KB)

    COA (232 KB) SDS-PAGE (92 KB) SEC-HPLC (197 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Blinatumomab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Blinatumomab853426-35-4bscCD19xCD3 AMG-103 MEDI-538 MT-103 BLINCYTOAMG103AMG 103AMG-103MEDI538MEDI 538MEDI-538MT103MT 103MT-103CD19bispecific monoclonal antibodyacute lymphoblastic leukemiaInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Blinatumomab
    Cat. No.:
    HY-P9963
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.